PUBLISHER: The Business Research Company | PRODUCT CODE: 1827019
PUBLISHER: The Business Research Company | PRODUCT CODE: 1827019
Hereditary Transthyretin Amyloidosis Global Market Report 2025
Hereditary transthyretin amyloidosis (hATTR) is a rare, inherited disorder caused by mutations in the TTR gene, leading to the misfolding and accumulation of transthyretin protein as amyloid deposits in various organs. This condition primarily impacts the nervous system, heart, and other tissues, resulting in progressive neuropathy and cardiomyopathy.
The main treatment types for hereditary transthyretin amyloidosis include oral administration, subcutaneous injection, and other methods. Oral treatments, such as tablets, capsules, or liquids, provide a convenient and patient-friendly option, improving accessibility and adherence. The drug classes used in treating hATTR amyloidosis include RNAi agents such as patisiran and small interfering RNAs (siRNAs) such as vutrisiran. These therapies are distributed through hospital pharmacies and retail pharmacies and are used in settings such as hospitals, clinics, and other healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The hereditary transthyretin amyloidosis market research report is one of a series of new reports from The Business Research Company that provides hereditary transthyretin amyloidosis market statistics, including the hereditary transthyretin amyloidosis industry global market size, regional shares, competitors with the hereditary transthyretin amyloidosis market share, detailed hereditary transthyretin amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary transthyretin amyloidosis industry. This hereditary transthyretin amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The hereditary transthyretin amyloidosis market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the rising incidence of this disorder, an increase in research and development activities, an increasing number of cardiac amyloidosis cases, growing disease awareness, and increasing healthcare infrastructure.
The hereditary transthyretin amyloidosis market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to a growing geriatric population, rising disposable incomes, increasing incidence of hereditary transthyretin amyloidosis, a rise in the development of new drugs, and a rise in genetic testing. Major trends in the forecast period include advanced treatment products, advancements in diagnostic techniques, advancements in drug development, demand for effective therapies, and advancements in medical technology.
The forecast of 9.0% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of RNAi therapeutics and Transthyretin(TTR) stabilizers sourced from the Netherlands and Ireland, exacerbating out-of-pocket expenses and limiting early intervention. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing geriatric population is expected to drive the growth of the hereditary transthyretin amyloidosis market. This population, defined as individuals aged 65 and older, often requires specialized healthcare due to the aging process. The growth in this demographic is fueled by rising life expectancy, thanks to advancements in healthcare and living standards. Hereditary transthyretin amyloidosis (hATTR) particularly affects the elderly, causing progressive neuropathy and cardiomyopathy, which increases morbidity in older individuals. According to the Population Reference Bureau, the U.S. population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. This growing geriatric population is contributing to the market's expansion.
Companies in the hereditary transthyretin amyloidosis market are developing cutting-edge therapeutics such as RNAi therapeutics to reduce the production of the transthyretin (TTR) protein. RNAi therapeutics use RNA interference technology to silence specific genes and reduce the production of proteins that cause diseases. For example, in October 2024, Alnylam Pharmaceuticals, Inc. submitted a supplemental new drug application (sNDA) to the U.S. FDA for Vutrisiran (AMVUTTRA) to treat transthyretin amyloidosis with cardiomyopathy. This RNAi therapy targets the TTR protein, a key player in the disease's progression. Vutrisiran's subcutaneous administration offers a more patient-friendly alternative to intravenous treatments, positioning it as a promising option for those affected by this severe condition.
In July 2023, Ionis Pharmaceuticals, Inc. entered into a partnership with AstraZeneca plc to co-develop and market eplontersen for treating transthyretin amyloidosis (ATTR) in the U.S. This collaboration also aims to enhance global access to the therapy by leveraging AstraZeneca's broad commercial presence, particularly in Latin America and other international regions. AstraZeneca is a UK-based biopharmaceutical company specializing in the discovery, development, and commercialization of prescription medicines.
Major players in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, and Autotac Bio Inc.
North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hereditary transthyretin amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hereditary transthyretin amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hereditary transthyretin amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and genetic counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary transthyretin amyloidosis market also includes sales of genetic testing kits, imaging technologies, biomarkers, and assays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hereditary Transthyretin Amyloidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hereditary transthyretin amyloidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for hereditary transthyretin amyloidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hereditary transthyretin amyloidosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Oral; Subcutaneous Injection; Other Types
- 2) By Drug Class: RNAi Agents (Patisiran); Small Interfering RNAs (siRNAs) (Vutrisiran)
- 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
- 4) By Application: Hospital; Clinic; Other Applications
- Subsegments:
- 1) By Oral: Tafamidis; Diflunisal; Experimental Oral Therapies
- 2) By Subcutaneous Injection: Patisiran; Inotersen; Vutrisiran
- 3) By Other Types: Intravenous Therapies; Gene Silencing Therapies; CRISPR-Based Therapies
- Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; AstraZeneca plc; Novo Nordisk; Regeneron Pharmaceuticals Inc.; Alexion Pharmaceuticals Inc.; Alnylam Pharmaceuticals Inc.; PTC Therapeutics Inc.; Ionis Pharmaceuticals Inc.; BridgeBio Pharma Inc.; Akcea Therapeutics; Prothena Corporation plc; Intellia Therapeutics Inc.; YoITech Therapeutics; Corino Therapeutics Inc.; Attralus Inc.; BSIM Therapeutics SA; Eidos Therapeutics; Autotac Bio Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Hereditary Transthyretin Amyloidosis Market Characteristics
3. Hereditary Transthyretin Amyloidosis Market Trends And Strategies
4. Hereditary Transthyretin Amyloidosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Hereditary Transthyretin Amyloidosis Growth Analysis And Strategic Analysis Framework
- 5.1. Global Hereditary Transthyretin Amyloidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Hereditary Transthyretin Amyloidosis Market Growth Rate Analysis
- 5.4. Global Hereditary Transthyretin Amyloidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Hereditary Transthyretin Amyloidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Hereditary Transthyretin Amyloidosis Total Addressable Market (TAM)
6. Hereditary Transthyretin Amyloidosis Market Segmentation
- 6.1. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Subcutaneous Injection
- Other Types
- 6.2. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- RNAi Agents (Patisiran)
- Small Interfering RNAs (siRNAs) (Vutrisiran)
- 6.3. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- 6.4. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital
- Clinic
- Other Applications
- 6.5. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tafamidis
- Diflunisal
- Experimental Oral Therapies
- 6.6. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Subcutaneous Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Patisiran
- Inotersen
- Vutrisiran
- 6.7. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravenous Therapies
- Gene Silencing Therapies
- CRISPR-Based Therapies
7. Hereditary Transthyretin Amyloidosis Market Regional And Country Analysis
- 7.1. Global Hereditary Transthyretin Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Hereditary Transthyretin Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Hereditary Transthyretin Amyloidosis Market
- 8.1. Asia-Pacific Hereditary Transthyretin Amyloidosis Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Hereditary Transthyretin Amyloidosis Market
- 9.1. China Hereditary Transthyretin Amyloidosis Market Overview
- 9.2. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Hereditary Transthyretin Amyloidosis Market
- 10.1. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Hereditary Transthyretin Amyloidosis Market
- 11.1. Japan Hereditary Transthyretin Amyloidosis Market Overview
- 11.2. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Hereditary Transthyretin Amyloidosis Market
- 12.1. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Hereditary Transthyretin Amyloidosis Market
- 13.1. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Hereditary Transthyretin Amyloidosis Market
- 14.1. South Korea Hereditary Transthyretin Amyloidosis Market Overview
- 14.2. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Hereditary Transthyretin Amyloidosis Market
- 15.1. Western Europe Hereditary Transthyretin Amyloidosis Market Overview
- 15.2. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Hereditary Transthyretin Amyloidosis Market
- 16.1. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Hereditary Transthyretin Amyloidosis Market
- 17.1. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Hereditary Transthyretin Amyloidosis Market
- 18.1. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Hereditary Transthyretin Amyloidosis Market
- 19.1. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Hereditary Transthyretin Amyloidosis Market
- 20.1. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Hereditary Transthyretin Amyloidosis Market
- 21.1. Eastern Europe Hereditary Transthyretin Amyloidosis Market Overview
- 21.2. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Hereditary Transthyretin Amyloidosis Market
- 22.1. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Hereditary Transthyretin Amyloidosis Market
- 23.1. North America Hereditary Transthyretin Amyloidosis Market Overview
- 23.2. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Hereditary Transthyretin Amyloidosis Market
- 24.1. USA Hereditary Transthyretin Amyloidosis Market Overview
- 24.2. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Hereditary Transthyretin Amyloidosis Market
- 25.1. Canada Hereditary Transthyretin Amyloidosis Market Overview
- 25.2. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Hereditary Transthyretin Amyloidosis Market
- 26.1. South America Hereditary Transthyretin Amyloidosis Market Overview
- 26.2. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Hereditary Transthyretin Amyloidosis Market
- 27.1. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Hereditary Transthyretin Amyloidosis Market
- 28.1. Middle East Hereditary Transthyretin Amyloidosis Market Overview
- 28.2. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Hereditary Transthyretin Amyloidosis Market
- 29.1. Africa Hereditary Transthyretin Amyloidosis Market Overview
- 29.2. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Hereditary Transthyretin Amyloidosis Market Competitive Landscape And Company Profiles
- 30.1. Hereditary Transthyretin Amyloidosis Market Competitive Landscape
- 30.2. Hereditary Transthyretin Amyloidosis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis
31. Hereditary Transthyretin Amyloidosis Market Other Major And Innovative Companies
- 31.1. Regeneron Pharmaceuticals Inc.
- 31.2. Alexion Pharmaceuticals Inc.
- 31.3. Alnylam Pharmaceuticals Inc.
- 31.4. PTC Therapeutics Inc.
- 31.5. Ionis Pharmaceuticals Inc.
- 31.6. BridgeBio Pharma Inc.
- 31.7. Akcea Therapeutics
- 31.8. Prothena Corporation plc
- 31.9. Intellia Therapeutics Inc.
- 31.10. YoITech Therapeutics
- 31.11. Corino Therapeutics Inc.
- 31.12. Attralus Inc.
- 31.13. BSIM Therapeutics SA
- 31.14. Eidos Therapeutics
- 31.15. Autotac Bio Inc
32. Global Hereditary Transthyretin Amyloidosis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Hereditary Transthyretin Amyloidosis Market
34. Recent Developments In The Hereditary Transthyretin Amyloidosis Market
35. Hereditary Transthyretin Amyloidosis Market High Potential Countries, Segments and Strategies
- 35.1 Hereditary Transthyretin Amyloidosis Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Hereditary Transthyretin Amyloidosis Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Hereditary Transthyretin Amyloidosis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
